论文部分内容阅读
目的:探讨他汀类药物在急性心肌梗死患者中使用的疗效及用药安全性。方法:将752例急性心肌梗死患者随机分成两组,治疗组使用他汀类药物,对照组采取非他汀类药物治疗,观察两组患者心肌酶(CK)及心肌酶同工酶(CK-MB)、低密度脂蛋白(LDL)、发生充血性心力衰竭和死亡率的情况。结果:治疗组服用他汀类药物的患者血液的CK、CK-MB、LDL水平和死亡率、再发心梗入院率明显低于对照组(P<0.05),发展为充血性心力衰竭(CHF)的风险低。治疗组患者不良反应的发生率很低,2例出现肝功能损害,1例出现轻微的肌无力症状,均在停药后症状自行消失。结论:早期使用他汀类药物对急性心梗患者有明显疗效,能够减少死亡率和发展为CHF的可能性,建议临床上进一步推广。
Objective: To investigate the efficacy and safety of statins used in patients with acute myocardial infarction. Methods: A total of 752 AMI patients were randomly divided into two groups: the statin group was used in the treatment group and the non-statin group was used in the control group. The levels of CK and CK- , Low density lipoprotein (LDL), congestive heart failure and mortality. Results: The levels of CK, CK-MB and LDL in the blood of patients taking statins in the treatment group were significantly lower than those in the control group (P <0.05) The risk is low. In the treatment group, the incidence of adverse reactions was very low, liver function impairment occurred in 2 cases and mild myasthenia symptom in 1 case, all the symptoms disappeared after withdrawal. CONCLUSIONS: Early use of statins has shown significant efficacy in patients with AMI, reducing mortality and developing the possibility of CHF, and is recommended for further clinical use.